Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.77 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | PREP | P48147 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.55 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 2/20 | 0.55 |
| ▸ | EP300 | Q09472 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297416 | 0.99 | P2RX7 (0.77) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL918260 | 0.95 | P2RX7 (0.75) | P2RX7BCHEACHEPREPALDH1A1 | |
| SCHEMBL18297397 | 0.94 | P2RX7 (0.74) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL918083 | 0.93 | P2RX7 (0.77) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL917668 | 0.92 | P2RX7 (0.76) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL918233 | 0.92 | P2RX7 (0.76) | P2RX7BCHEACHEALDH1A1LMNA | |
| Iodide SCHEMBL918256 | 0.92 | P2RX7 (0.76) | P2RX7BCHEACHEPREPALDH1A1 | |
| SCHEMBL18297413 | 0.92 | P2RX7 (0.77) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL917204 | 0.92 | P2RX7 (0.78) | P2RX7BCHEACHEPREPALDH1A1 | |
| Iodide SCHEMBL918242 | 0.92 | P2RX7 (0.70) | P2RX7BCHEACHEPREPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456770-A2 | BENZOQUINOLIZINIUM SALT DERIVATIVES AS ANTICANCER AGENTS | Naxospharma S.R.L. (IT) | 2012-05-30 | — | — | EP | claimed |
| US-8188109-B2 | Benzoquinolizinium salt derivatives as anticancer agents | NAXOSPHARMA S.R.L. (IT) | 2012-05-29 | — | — | US | claimed |
| WO-2011009714-A2 | BENZOQUINOLIZINIUM SALT DERIVATIVES AS ANTICANCER AGENTS | NAXOSPHARMA S.R.L. (IT) | 2011-01-27 | — | — | WO | claimed |
| US-20110015222-A1 | Benzoquinolizinium salt derivatives as anticancer agents | NAXOSPHARMA S.R.L. | 2011-01-20 | — | — | US | claimed |
| EP-2456770-B1 | BENZOQUINOLIZINIUM SALT DERIVATIVES AS ANTICANCER AGENTS | NAXOSPHARMA S R L (IT) | 2016-12-14 | — | — | EP | disclosed |
| US-8188109-B2 | Benzoquinolizinium salt derivatives as anticancer agents | NAXOSPHARMA S.R.L. (IT) | 2012-05-29 | — | — | US | disclosed |
| US-20110015222-A1 | Benzoquinolizinium salt derivatives as anticancer agents | NAXOSPHARMA S.R.L. | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015222-A1 | Benzoquinolizinium salt derivatives as anticancer agents | NQO2, VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACHE 3155/4885CHRM1 4376/4885P2RX7 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.